Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06478186

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06478186
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06478186. Randomized; triple masking; primary purpose treatment. Start 2024-08-16 (actual); primary completion 2026-12-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
Condition
Osteoarthritis, Knee
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
triamcinolone acetonide extended-release injectable suspension; TCA-ER
Intervention (Drug)
Triamcinolone Acetonide- Immediate Release;TCA-IR
Lead sponsor
University of Kansas Medical Center (class: other)

Record details

Record id
cardio:ct-nct06478186
Content hash
ca2db85a050e5717c3cad40172d7ba9fe0f9703d51dcf4687fde24852f355073